(Total Views: 352)
Posted On: 10/18/2019 12:49:54 PM
Post# of 154082
MAT 9001 can be approved for treating high triglycerides without an outcomes study.
Physicians will then be able to prescribe MAT 9001 for whatever Vascepa is prescribed for.
If MAT 9001 again handily bests Vascepa in another head-to-head trial, I would venture to guess that many would prescribe MAT 9001 for conditions for which Vascepa, but not MAT 9001, has been approved for.
Even if not, there is a very large market for drugs that treat high trigylcerides, and with another successful head-to-head trial against Vascepa, MAT 9001 is likely to become the market leader for this indication.
The market cap for Matinas is a small fraction of Amarin, which I think makes Matinas a good investment.
I am a big early investor in Matinas, so I obviously believe in the company, and am hoping for its success.
All in my opinion.
LM
Physicians will then be able to prescribe MAT 9001 for whatever Vascepa is prescribed for.
If MAT 9001 again handily bests Vascepa in another head-to-head trial, I would venture to guess that many would prescribe MAT 9001 for conditions for which Vascepa, but not MAT 9001, has been approved for.
Even if not, there is a very large market for drugs that treat high trigylcerides, and with another successful head-to-head trial against Vascepa, MAT 9001 is likely to become the market leader for this indication.
The market cap for Matinas is a small fraction of Amarin, which I think makes Matinas a good investment.
I am a big early investor in Matinas, so I obviously believe in the company, and am hoping for its success.
All in my opinion.
LM
(1)
(0)
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
